Parth Mehrotra - 27 Mar 2023 Form 4 Insider Report for Privia Health Group, Inc. (PRVA)

Role
President and COO
Signature
/s/ Thomas Bartrum, as attorney-in-fact
Issuer symbol
PRVA
Transactions as of
27 Mar 2023
Net transactions value
-$478,715
Form type
4
Filing time
29 Mar 2023, 16:21:38 UTC
Previous filing
13 Mar 2023
Next filing
31 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRVA Common Stock, $0.01 par value per share Options Exercise $26,508 +13,254 +14% $2.00* 110,645 27 Mar 2023 Direct
transaction PRVA Common Stock, $0.01 par value per share Sale $371,377 -13,254 -12% $28.02 97,391 27 Mar 2023 Direct F1, F2
transaction PRVA Common Stock, $0.01 par value per share Options Exercise $10,280 +5,140 +5.3% $2.00* 102,531 28 Mar 2023 Direct
transaction PRVA Common Stock, $0.01 par value per share Sale $144,126 -5,140 -5% $28.04 97,391 28 Mar 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRVA Stock Option (Right to Purchase) Options Exercise $0 -6,887 -2.5% $0.000000 273,559 27 Mar 2023 Common Stock 6,887 $2.00 Direct F4
transaction PRVA Stock Option (Right to Purchase) Options Exercise $0 -6,367 -2.3% $0.000000 266,010 27 Mar 2023 Common Stock 6,367 $2.00 Direct F4
transaction PRVA Stock Option (Right to Purchase) Options Exercise $0 -5,140 -1.9% $0.000000 260,870 28 Mar 2023 Common Stock 5,140 $2.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.11 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.17 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 All stock options are fully vested and exercisable.